AbCellera Biologics Inc. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
AbCellera Biologics Inc. (ABCL) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $3.73 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2025-11-06
- 2025-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $3.73M.
- 2025-06-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $3.73M.
- 2025-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $3.73M.
- 2024-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $4.30M.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months |
|---|---|
| 2025-09-30 | $3.73M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $3.73M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.73M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $4.30M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $4.30M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $4.30M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |